High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data
Top Cited Papers
- 1 July 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Epidemiology
- Vol. 20 (4) , 512-522
- https://doi.org/10.1097/ede.0b013e3181a663cc
Abstract
Background: Adjusting for large numbers of covariates ascertained from patients’ health care claims data may improve control of confounding, as these variables may collectively be proxies for unobserved factors. Here, we develop and test an algorithm that empirically identifies candidate covariates, prioritizes covariates, and integrates them into a propensity-score-based confounder adjustment model. Methods: We developed a multistep algorithm to implement high-dimensional proxy adjustment in claims data. Steps include (1) identifying data dimensions, eg, diagnoses, procedures, and medications; (2) empirically identifying candidate covariates; (3) assessing recurrence of codes; (4) prioritizing covariates; (5) selecting covariates for adjustment; (6) estimating the exposure propensity score; and (7) estimating an outcome model. This algorithm was tested in Medicare claims data, including a study on the effect of Cox-2 inhibitors on reduced gastric toxicity compared with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). Results: In a population of 49,653 new users of Cox-2 inhibitors or nonselective NSAIDs, a crude relative risk (RR) for upper GI toxicity (RR = 1.09 [95% confidence interval = 0.91–1.30]) was initially observed. Adjusting for 15 predefined covariates resulted in a possible gastroprotective effect (0.94 [0.78–1.12]). A gastroprotective effect became stronger when adjusting for an additional 500 algorithm-derived covariates (0.88 [0.73–1.06]). Results of a study on the effect of statin on reduced mortality were similar. Using the algorithm adjustment confirmed a null finding between influenza vaccination and hip fracture (1.02 [0.85–1.21]). Conclusions: In typical pharmacoepidemiologic studies, the proposed high-dimensional propensity score resulted in improved effect estimates compared with adjustment limited to predefined covariates, when benchmarked against results expected from randomized trials.Keywords
This publication has 39 references indexed in Scilit:
- Impact of mis‐specification of the treatment model on estimates from a marginal structural modelStatistics in Medicine, 2008
- Invited Commentary: Variable Selection versus Shrinkage in the Control of Multiple ConfoundersAmerican Journal of Epidemiology, 2007
- Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial ResultsMedical Care, 2007
- Understanding secondary databases: a commentary on “Sources of bias for health state characteristics in secondary databases”Journal of Clinical Epidemiology, 2007
- Simultaneous assessment of short‐term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: An instrumental variable analysisArthritis & Rheumatism, 2006
- The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48 000 initiators of statin therapyPharmacoepidemiology and Drug Safety, 2006
- Variable Selection for Propensity Score ModelsAmerican Journal of Epidemiology, 2006
- A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methodsJournal of Clinical Epidemiology, 2005
- Meta‐analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase‐2‐specific inhibitor, compared with nonspecific nonsteroidal anti‐inflammatory drugs among patients with osteoarthritis and rheumatoid arthritisAlimentary Pharmacology & Therapeutics, 2005
- Spurious effects from an extraneous variableJournal of Chronic Diseases, 1966